Market Outlook The last pattern detected was bullish with positive implications. The overall evidence, however, is saying “Watch Out!” but it is not yet pointing to BUY. The share price is still not above the confirmation level and the signal is suggesting to STAY IN CASH, but the chance of a bullish confirmation that will change the signal to BUY is quite high.
Conclusion CEO.. Changes already implemented and under way should lead to a significant improvement on the results achieved in the year ended 31 July 2013. Our future focus, on becoming a healthcare company with a broad product portfolio that helps people to maintain, re-gain or improve their physical, emotional and social health and wellbeing, will not only open new commercial opportunities, but mitigate the risks associated with being reliant on one product for revenue delivery, which has historically been our weakness. ((Next year is about successfully achieving three key objectives)): •Implementing the strategy agreed by the Board. •Increased revenues, with a return to profitability. •Looking to increase shareholder value through the achievement of the above. http://ultrasisplc.com/news/article/377.html
LONDON (Alliance News) - Interactive healthcare provider Ultrasis PLC Tuesday reported a wider loss and lower revenues form its last financial year, as it was hit by government changes to the way the UK's National Health Service procures services and by writeoffs and resignation payments. However, the company was more positive about its outlook due to recent acquisitions it has made, and as it tries to sell more of its services outside the UK. The company reported a pretax loss of GBP3.5 million for the year to end-July, compared with a loss of GBP1.4 million a year earlier, as revenues declined to GBP977,000, from GBP1.1 million and it wrote off nearly GBP2 million on the value of a license it got when it bought Healthstar in 2006. It also booked a GBP256,000 expense paid to former Chief Executive Nigel Brabbins in lieu of his notice period. Brabbins resigned in June "to pursue other interests". Excluding the one-off costs, the company's operating loss narrowed to GBP1.2 million, from last year's loss of GBP1.4 million as the company cut costs. Ultrasis was hard hit by changes being made to the NHS. Under government reforms, procurement of services has been taken away from the previous regional health authorities and handed to groups of doctors and other health practitioners known as clinical commissioning groups. The company said the changes delayed buying decisions and made it difficult to sell in its main market. However, it was more positive about the future. "I look forward to leading the Ultrasis Group at this exciting time, the structural changes and acquisitions we are currently making are only the start of our new strategy to create a company that helps people maintain, regain and improve their physical, psychological and social wellbeing," new CEO John Smith said in a statement. "I believe my clinical background, leadership experience and absolute belief in our products and services will enable me to transform the company into a profitable business and market leader," he added. Ultrasis, which has products including the "Beating the Blues" cognitive therapy platform for treating anxiety and depression, bought screening company Screenetics in September for GBP4.8 million and then physical activity tracking company Step Success for less than GBP30,000 last month. "The recent announcement that Screenetics, just six weeks after joining the Ultrasis Group, has secured contracts which will add approximately GBP2 million per annum to Group revenues is early evidence that rapid growth by acquisition is an attainable goal," the company said. "In October, shareholders gave the board sufficient authority to issue shares to enable the company to take advantage of future suitable acquisition opportunities," it added. The company had cash reserves of GBP734,000 at the end of its last financial year, down from GBP1.4 million a year earlier, but it had unus
Not sure why that wasn't included in the results, maybe tested the water first imo. China a back up if results were badly received by the market, just a thought. On the assumption.trials were successful ?? The company said results from china would be before christmas, before autumn expires.
Thats what we are waiting for then hopefully we are away
Does someone know something because the the buys are coming in, or is it that they know this will sore very soon its just a matter of time
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.